Helicobacter pylori Infection Enhances Gastric Mucosal Inflammation in Individuals Carrying the 260-T Allele of the CD14 Gene

Combined risk factors and risk of upper gastrointestinal cancer mortality in the Linxian general population

We aimed to explore the association of combined risk factors with risk of death from upper gastrointestinal (UGI) cancer, including esophageal squamous cell carcinoma (ESCC), gastric cardia carcinoma (GCC) and gastric noncardia carcinoma (GNCC) in the Linxian Nutrition Intervention Trial (NIT) cohort. The NIT cohort included 29 584 healthy adults. A combined risk score (CRS) was calculated using a point system method based on 10 risk factors collected at baseline, including gender, smoking, alcohol drinking, body mass index, family history of UGI cancer, drinking tap water, tooth loss and consumption of fresh fruit, eggs and meat. Possible score ranged from 0 to 31, and higher score indicated as poorer health status. Subjects were divided into three groups by the CRS (<12 points, 12 to 20 points and >20 points). The group of CRS <12 points was considered as the reference. During the 30-year follow-up, we identified 4553 UGI cancer deaths. Compared to subjects with a CRS <12 points, the adjusted HRs for CRS of 12 to 20 points and >20 points were 1.69 (95% CI: 1.56-1.83) and 3.06 (95% CI: 2.82-3.33) for UGI cancer mortality, respectively (P_trend  < .001). Comparable associations were also observed for ESCC, GCC and GNCC mortality. Results remained similar across different age groups (P_interaction  > .05). All HRs observed in the second half follow-up period were stronger than that observed in the first half follow-up period. Our study indicated that higher CRS was associated with increased risk of UGI cancer mortality. Appropriate measures should be taken to reduce unhealthy lifestyles.

Association between CD14 SNP -159 C/T and gastric cancer: an independent case-control study and an updated meta-analysis

PURPOSE

The association between CD14 -159C/T polymorphism and the susceptibility to gastric cancer (GC) has been reported. However, the results were inconclusive. In the present study, a case-control study and a meta-analysis were performed to assess the possible association between -159C/T in the CD14 gene and GC risk.

PATIENTS AND METHODS

Relevant studies were searched in several databases including PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure database, and Wanfang database (last search was performed on December 30, 2015). In addition, a case-control study involving 164 GC cases and 169 controls was also performed in the analysis. Statistical analysis was performed by the software Revman5.3.

RESULTS

A total of ten published studies and the present case-control study involving 2,844 GC and 3,983 controls were included for the meta-analysis. The analysis result indicated that the T allele of CD14 -159C/T polymorphism did not confer risk for GC (in our study: [P=0.93]; in the meta-analysis: T vs 2N odds ratio =1.28 and 95% confidence interval (CI) =0.95-1.24, [P=0.24]). However, we found a significant association in the recessive model (in our study: TT vs TC+CC [P=0.04]; in the meta-analysis: TT vs TC+CC odds ratio =1.12 and 95% CI =1.01-1.26, [P=0.04]). Furthermore, a subgroup analysis by ethnicity showed that TT genotype was significantly associated with GC in Asian (odds ratio =1.17 and 95% CI =1.02-1.34, [P=0.02]) but not in Caucasian.

CONCLUSION

Our results highlight the TT genotype of CD14 -159C/T as a genetic susceptibility factor for gastric cancer, particularly, in Asians and population-based controls.

Construction of a gastric cancer cell line with stably silenced expression of CD14

AIM: To develop a SGC-7901 cell line with stably silenced expression of CD14 to provide an experimental basis for the study of the pathogenesis of gastric cancer.

METHODS: A CD14-shRNA lentiviral vector was constructed to transfect gastric cancer SGC-7901 cells. RT-PCR and Western blot were used to detect the CD14 mRNA and protein levels in untreated SGC-7901 cells (blank control group), SGC-7901 cells transfected with NC-CD14 shRNA (NC-CD14 shRNA control group) and SGC-7901 cells transfected with the CD14-shRNA lentiviral vector (CD14-shRNA lentiviral vector group).

RESULTS: CD14-shRNA expression vector was successfully constructed and transfected into gastric cancer cells. RT-PCR showed that the Ct value for the CD14-shRNA lentiviral vector group was significantly higher than those for the NC-CD14 shRNA control group and blank control group (P = 0.000; P < 0.001), and the 2^Ct value for the CD14-shRNA lentiviral vector group (1±0.08) was significantly lower than those for the NC-CD14 shRNA control group and blank control group (P = 0.0001; P < 0.001). Western blot analysis showed that the relative expression of CD14 protein in the CD14-shRNA lentiviral vector group (0.01) was significantly less than that in the blank control group (1.0) and NC-CD14 shRNA control group (0.83).

CONCLUSION: A CD14-shRNA lentiviral vector has been successfully transfected into gastric cancer SGC-7901 cells, which can inhibit the expression of CD14 mRNA and protein in SGC-7901 cells.